Status:
UNKNOWN
De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)
Lead Sponsor:
National Research Center for Hematology, Russia
Conditions:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
No high-dose methotrexate (MTX) and high-dose cytarabine (ARA-C) consolidation blocks, L-asparaginaseis scheduled for 1 year of treatment, 21 intrathecal injections through the whole treament, T-ALL p...
Detailed Description
* 7 days prednisolone prephase * 8 weeks induction with de-escalation of induction chemotherapy: 3 instead of 4 dauno/vncr pulses, 1. instead of 2 Cph injections during induction, 2. instead of 4...
Eligibility Criteria
Inclusion
- age 18-55 yy, newly diagnosed non-treated Ph-negative ALL
Exclusion
- age \> 55 yy, Ph-positivity, relapsed\|refractory ALL, pretreated ALL
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT03462095
Start Date
January 1 2017
End Date
December 1 2022
Last Update
March 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Research Center for Hematology
Moscow, Russia, 125167